More Cynata Therapeutics Limited news
Cynata Therapeutics LimitedASX: CYP

First Patient Enrolled in Cynata MEND Clinical Trial

May 24, 2021 at 2:30 AM EDT · Issued by Cynata Therapeutics Limited

Filed with ASX · May 24, 2021 at 2:30 AM EDT · 2 pages · English

On 6ix: 6ix.com/news/first-patient-enrolled-in-cynata-mend-clinical-trial

Cynata Therapeutics Limited on 6ix

Earlier from Cynata Therapeutics

  • Cynata Therapeutics Expands MEND clinical trial in COVID-19 and Respiratory FailureMar 29, 2021
  • Cynata Expands trial in COVID-19 & Respiratory FailureMar 28, 2021
  • New Preclinical Study to Investigate the High Potency of Cymerus™ MSCsMar 2, 2021
  • Cynata Therapeutics Advances Planned Clinical Trial in Diabetic Foot Ulcers in MoU With TekCyteMar 1, 2021
  • Cynata Receives $1.39m R&D Tax Incentive RefundFeb 21, 2021

Later from Cynata Therapeutics

  • Cynata signs Licence Agreement with TekCyteJun 3, 2021
  • Progress Toward Clinical Trial in Diabetic Foot UlcersJun 27, 2021
  • Ethics Approval for Cynatas Clinical Trial in DFUJun 30, 2021
  • Cynata Receives Notice of Allowance from US Patent OfficeAug 26, 2021
  • Further Canadian Patent for CynataAug 30, 2021
All Cynata Therapeutics news releases↗

Follow Cynata Therapeutics into a list and get an email when it puts out news.

Follow Cynata Therapeutics
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer